George Dangas, MD, PhD
Coronary artery disease (CAD) is a common co-morbidity amongst patients undergoing transcatheter aortic valve replacement (TAVR) and studies provide conflicting data on its prognostic impact. In addition, the optimal periprocedural anticoagulation in patients with CAD undergoing TAVR remains unknown. This analysis aims to evaluate the effect of CAD on clinical outcomes following TAVR and the interaction between CAD and different periprocedural anticoagulants.